SCYX Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga - Mentions: PACS GNTA NCNA REVB ...

12 Health Care Stocks Moving In Thursday's After-Market Session

a month ago - By: Scynexis

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

a month ago - By: Scynexis

Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

2 months ago - By: Scynexis

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Scynexis

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

2 years ago - By: InvestorPlace - Mentions: BVS IMMR

3 Stocks Under $10 With Mammoth Growth Prospects

2 years ago - By: BusinessInsider

SCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024

3 months ago - By: Benzinga - Mentions: BOLT GOVX LPTX IMTX ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

4 months ago - By: Scynexis

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

4 months ago - By: Scynexis

SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025

4 months ago - By: Scynexis

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

7 months ago - By: Yahoo Finance - Mentions: REGN TBIO PEPG NVDA ...

Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&D Efficiency

7 months ago - By: Yahoo Finance - Mentions: PEPG X REGN TM ...

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

7 months ago - By: Yahoo Finance - Mentions: IMNN SIRI CVNA PEPG ...

Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More

7 months ago - By: Yahoo Finance - Mentions: SHOP ONON BROS REGN ...

3 Monster Stocks to Hold for the Next 20 Years

7 months ago - By: Yahoo Finance - Mentions: NOVA PEPG TSLA TTE ...

Trump administration cancels Sunnova's $2.92 billion government loan guarantee

7 months ago - By: Scynexis

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

7 months ago - By: Scynexis

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

9 months ago - By: Scynexis

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

a year ago - By: Scynexis

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

a year ago - By: Scynexis

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

a year ago - By: Scynexis

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

a year ago - By: Scynexis

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

a year ago - By: Scynexis

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

a year ago - By: InvestorPlace

SCYX Stock Earnings: SCYNEXIS Misses EPS, Misses Revenue for Q2 2024

a year ago - By: Scynexis

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

a year ago - By: InvestorPlace - Mentions: WRNT NMHI SOAR FEIM ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

a year ago - By: Scynexis

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

a year ago - By: InvestorPlace - Mentions: SOFI INGN GSK

3 Stocks Under $10 With the Potential for Massive Gains

a year ago - By: InvestorPlace - Mentions: ATAI ATOS CMPS GSK

3 Dirt-Cheap Drug Developers With Blockbuster Potential

a year ago - By: InvestorPlace - Mentions: PROC MDXG MEIP INCY ...

7 Undervalued Biotech Stocks to Buy for Big-Time Returns

2 years ago - By: InvestorPlace - Mentions: HRTG IMMR

SCYNEXIS INC (SCYX) Stock News

SCYX Latest News, Press Relases and Analysis

12 Health Care Stocks Moving In Thursday's After-Market Session

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

3 Stocks Under $10 With Mammoth Growth Prospects

SCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024

12 Health Care Stocks Moving In Thursday's Pre-Market Session

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&D Efficiency

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More

3 Monster Stocks to Hold for the Next 20 Years

Trump administration cancels Sunnova's $2.92 billion government loan guarantee

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

SCYX Stock Earnings: SCYNEXIS Misses EPS, Misses Revenue for Q2 2024

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

3 Stocks Under $10 With the Potential for Massive Gains

3 Dirt-Cheap Drug Developers With Blockbuster Potential

7 Undervalued Biotech Stocks to Buy for Big-Time Returns

Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025